TimesSquare Capital Management LLC Buys 10,955 Shares of argenx SE (NASDAQ:ARGX)

TimesSquare Capital Management LLC lifted its position in argenx SE (NASDAQ:ARGX) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 112,705 shares of the company’s stock after purchasing an additional 10,955 shares during the quarter. TimesSquare Capital Management LLC owned about 0.19% of argenx worth $42,876,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Nkcfo LLC increased its stake in argenx by 22.1% in the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after acquiring an additional 21 shares during the last quarter. Genus Capital Management Inc. lifted its position in argenx by 1.6% during the third quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock valued at $789,000 after purchasing an additional 25 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of argenx by 2.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock worth $582,000 after buying an additional 41 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of argenx by 2.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,752 shares of the company’s stock worth $861,000 after buying an additional 46 shares during the last quarter. Finally, New York Life Investment Management LLC lifted its holdings in shares of argenx by 5.2% in the 4th quarter. New York Life Investment Management LLC now owns 978 shares of the company’s stock valued at $372,000 after acquiring an additional 48 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Stock Down 0.9 %

Shares of NASDAQ ARGX traded down $3.53 during trading hours on Thursday, hitting $382.55. 602,790 shares of the stock were exchanged, compared to its average volume of 311,010. The company has a market cap of $22.74 billion, a PE ratio of -70.60 and a beta of 0.67. argenx SE has a 12 month low of $327.73 and a 12 month high of $550.76. The firm has a fifty day moving average price of $382.97 and a 200-day moving average price of $410.51.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The business had revenue of $417.84 million for the quarter, compared to analysts’ expectations of $378.60 million. During the same quarter in the previous year, the firm posted ($0.70) EPS. As a group, equities analysts anticipate that argenx SE will post -2.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Scotiabank upped their price objective on argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 26th. Robert W. Baird reduced their price objective on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Wells Fargo & Company boosted their target price on argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th. Piper Sandler increased their price target on argenx from $518.00 to $522.00 and gave the stock an “overweight” rating in a report on Friday, January 26th. Finally, Wolfe Research started coverage on argenx in a research report on Thursday, February 15th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $528.16.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.